

10<sup>th</sup> August, 2021

CIN: L55101TG1973PLC040558

<b>The Secretary,</b> <b>Bombay Stock Exchange Ltd (BSE)</b> Phiroze Jheejeebhoy Towers, Dalal Street, Mumbai - 400 001. <b>Scrip Code - 543308</b> <b>ISIN: INE967H01017</b>	<b>The Secretary,</b> <b>National Stock Exchange, Exchange</b> Plaza, 5th Floor Plot No.C/1, 'G' Block Bandra - Kurla Complex Mumbai - 400 051. <b>Symbol - KIMS</b> <b>ISIN: INE967H01017</b>
---	--

Dear Sir,

**Sub:** Outcome of Board Meeting held on 10<sup>th</sup> August, 2021 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Reg.

With reference to the subject cited, please find enclosed herewith the Unaudited Financial results (Both Standalone and Consolidated) for the 1<sup>st</sup> Quarter ended 30<sup>th</sup> June, 2021 together with Limited Review Report which has been reviewed by Audit Committee and approved by Board of Directors.

The said documents are also being uploaded on the website of the Company i.e., <https://www.kimshospitals.com/stakeholder-relations/>

Further, the financial results will also be published in the newspapers as per the requirement and in the format prescribed under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 4.00 PM and concluded at 6.10 PM

Please take this intimation on record.

Thanking you,

For Krishna Institute of Medical Sciences Limited



Umashankar Mantha

Company Secretary & Compliance Officer



**Krishna Institute of Medical Sciences Limited**

Minister Road, Secunderabad - 500 003, Telangana, India

Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com

CIN: U55101TG1973PLC040558

**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2021 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.no.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Cuddles Private Limited*	Subsidiary
10	KIMS Hospital (Bhubaneswar) Private Limited	Subsidiary

\* the subsidiary has filed necessary closure forms for strike off with RoC on February 9, 2021



# S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

## Other matters

6. The accompanying Statement includes the unaudited interim financial results and other financial information in respect of:
- Four subsidiaries, whose unaudited interim financial results include total revenues of Rs Nil, total net loss after tax of Rs. 0.87 million, total comprehensive loss of Rs. 0.87 million for the quarter ended 30 June 2021, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

7. The Statement includes the results for the corresponding quarter ended 30 June 2020 and for the previous quarter 31 March 2021 as reported in these Unaudited Financial Results have been prepared solely based on the information compiled by the management, and have not been subject to audit or review.

Our conclusion on the Statement is not modified in respect of this matter.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004


*Navneet Rai*

per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 21102328AAAAFC4435



Place: Hyderabad


Date: 10 August 2021

**Krishna Institute of Medical Sciences Limited**  
Corporate Identity number : U55101TG1973PLC040558  
Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India  
Website: www.kimshospitals.com, Email: cs@kimshospitals.com, Tel: 040 7122 5000

**Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2021**

(Rupees in millions)

S.No.	Particulars	Quarter Ended			Year ended
		30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
		(Unaudited)	(Unaudited) Refer note 2	(Unaudited) Refer note 2	(Audited)
<b>1</b>	<b>Income</b>				
	(a) Revenue from operations	4,731.79	3,585.38	2,011.01	13,299.37
	(b) Other income	42.73	41.87	43.69	101.65
	<b>Total Income</b>	<b>4,774.52</b>	<b>3,627.25</b>	<b>2,054.70</b>	<b>13,401.02</b>
<b>2</b>	<b>Expenses</b>				
	(a) Purchase of medical consumables, drugs and surgical instruments	1,193.02	773.54	425.51	2,826.39
	(b) Decrease / (increase) in inventories of medical consumables, drugs and surgical instruments	(69.60)	(0.64)	4.21	62.92
	(c) Employee benefits expense	725.13	564.03	467.04	2,202.09
	(d) Other expenses	1,446.56	1,239.66	757.08	4,499.14
	(e) Finance cost	63.22	74.08	91.38	324.97
	(f) Depreciation and amortisation expense	170.88	166.38	169.42	695.36
	<b>Total Expenses</b>	<b>3,529.21</b>	<b>2,817.05</b>	<b>1,914.64</b>	<b>10,610.87</b>
<b>3</b>	<b>Profit before tax (1-2)</b>	<b>1,245.31</b>	<b>810.20</b>	<b>140.06</b>	<b>2,790.15</b>
<b>4</b>	<b>Tax expense</b>				
	(a) Current tax	338.07	233.37	59.90	778.39
	(b) Deferred tax credit	(13.06)	(10.01)	(9.08)	(33.03)
	(c) Adjustment of tax relating to earlier periods	-	0.63	-	(10.00)
	<b>Total tax expenses</b>	<b>325.01</b>	<b>223.99</b>	<b>50.82</b>	<b>735.36</b>
<b>5</b>	<b>Profit for the period/year (3-4)</b>	<b>920.30</b>	<b>586.21</b>	<b>89.24</b>	<b>2,054.79</b>
	<b>Attributable to:</b>				
	Owners of the Company	891.28	578.02	111.27	2,012.19
	Non-controlling interests	29.25	8.19	(22.27)	42.60
<b>6</b>	<b>Other comprehensive income</b>				
	Items that will not be reclassified subsequently to statement of profit and loss				
	- Re-measurement (loss)/gain on defined benefit plans	(1.47)	9.09	(3.16)	(6.28)
	- Income tax effect	0.38	(2.29)	0.80	1.64
	<b>Other comprehensive income, net of tax</b>	<b>(1.09)</b>	<b>6.80</b>	<b>(2.36)</b>	<b>(4.64)</b>
<b>7</b>	<b>Total comprehensive income for the period/year (5+6)</b>	<b>919.21</b>	<b>593.01</b>	<b>86.88</b>	<b>2,050.15</b>
	<b>Attributable to:</b>				
	Owners of the Company	(1.18)	6.42	(2.32)	(4.98)
	Non-controlling interests	0.10	0.38	(0.04)	0.34
<b>8</b>	<b>Paid up equity share capital (face value of Rs.10 each)</b>				<b>775.93</b>
<b>9</b>	<b>Other Equity</b>				<b>7,861.41</b>
<b>10</b>	<b>Earnings / (Loss) per share (of Rs.10 each) : (not annualised for the quarter ended)</b>				
	(a) Basic (Rs.)	11.48	7.72	1.49	26.87
	(b) Diluted (Rs.)	11.48	7.59	1.48	26.42



**Notes:**

- 1 In terms of Regulation 33 of the SFBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2021 ("Unaudited Consolidated Financial Results") of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 August 2021 and have been subject to a limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Consolidated financial results for the corresponding quarter ended 30 June 2020 and for the preceding quarter ended 31 March 2021, have not been subject to an audit or review by our statutory auditors. However, the management has exercised necessary due diligence to ensure that the Unaudited Consolidated financial results for these periods provide a true and fair view of the Group's affairs.
- 3 The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 4 The Company has completed Initial Public Offer ("IPO") of 25,995,042 Equity Shares of the face value of Rs. 10/- each at an issue price of Rs. 825/- per Equity Share, comprising offer for sale of 23,560,538 shares by Selling Shareholders and fresh issue of 2,434,504 shares. The Equity Shares of the Company were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on 28 June 2021. Accordingly, the Unaudited Consolidated Financial Results for the quarter ended 30 June 2021 are drawn up for the first time in accordance with the Listing requirements.
- 5 The utilisation of the net IPO proceeds is summarised below:

Particulars	Objects of the issue as per prospectus *	Utilisation upto 30 June 2021	Unutilised amount as on 30 June 2021
Repayment/pre-payment, in full or part, of certain borrowings availed by our Company and by our Subsidiaries	1,500.00	-	1,500.00
General Corporate Purpose	416.60	-	416.60
<b>Total</b>	<b>1,916.60</b>	<b>-</b>	<b>1,916.60</b>

\* net of Offer expenses to the extent applicable to the Fresh Issue.

IPO Proceeds, unutilised as at 30 June 2021, were temporarily invested in monitoring agency account.

- 6 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Group is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 7 The Group operates in one single reportable business segment - "Medical and Healthcare services".
- 8 The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Group is closely monitoring the impact of the pandemic on all aspects of its business, including how it will impact its employees, vendors and business partners. The Group based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact. Based on the current estimates, the Group expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Group will continue to closely monitor any material changes to future economic condition.
- 9 The above Unaudited Consolidated Financial Results of the Group are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.

For and on behalf of the Board

Krishna Institute of Medical Sciences Limited



*(Signature)*

Dr. B Bhaskara Rao

Managing Director

DIN: 00008985

Hyderabad  
10 August 2021



**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended 30 June 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

## **Other matters**

5. The Statement includes the results for the corresponding quarter ended 30 June 2020 and for the previous quarter 31 March 2021 as reported in these Unaudited Financial Results have been prepared solely based on the information compiled by the management, and have not been subject to audit or review.

Our conclusion on the Statement is not modified in respect of this matter.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm registration number: 101049W/E300004


*Navneet Rai Kabra*

per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 21102328AAAAFB9445



Hyderabad

10 August 2021

**Krishna Institute of Medical Sciences Limited**

Corporate Identity number : U55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: cs@kimshospitals.com, Tel: 040 7122 5000

**Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2021**

(Rupees in millions)

S.No.	Particulars	Quarter Ended			Year ended
		30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
		(Unaudited)	(Unaudited) Refer note 2	(Unaudited) Refer note 2	(Audited)
<b>1</b>	<b>Income</b>				
	(a) Revenue from operations	3,315.14	2,566.29	1,395.55	9,326.89
	(b) Other income	40.17	36.19	38.11	96.15
	<b>Total Income</b>	<b>3,355.31</b>	<b>2,602.48</b>	<b>1,433.66</b>	<b>9,423.04</b>
<b>2</b>	<b>Expenses</b>				
	(a) Purchase of medical consumables, drugs and surgical instruments	864.77	541.21	300.10	1,959.62
	(b) Decrease / (increase) in inventories of medical consumables, drugs and surgical instruments	(55.88)	(2.75)	7.07	52.34
	(c) Employee benefits expense	492.20	379.17	306.61	1,470.36
	(d) Other expenses	903.09	804.54	444.02	2,804.28
	(e) Finance cost	22.49	31.08	45.37	147.83
	(f) Depreciation and amortisation expense	107.36	105.51	103.43	445.98
	<b>Total Expenses</b>	<b>2,334.03</b>	<b>1,858.76</b>	<b>1,206.60</b>	<b>6,880.41</b>
<b>3</b>	<b>Profit before tax (1-2)</b>	<b>1,021.28</b>	<b>743.72</b>	<b>227.06</b>	<b>2,542.63</b>
<b>4</b>	<b>Tax expense</b>				
	(a) Current tax	263.54	204.78	55.54	668.12
	(b) Deferred tax charged/(credit)	(3.88)	7.95	1.60	(1.64)
	(c) Adjustment of tax relating to earlier periods	-	-	-	(10.34)
	<b>Total tax expenses</b>	<b>259.66</b>	<b>212.73</b>	<b>57.14</b>	<b>656.14</b>
<b>5</b>	<b>Profit for the period/year (3-4)</b>	<b>761.62</b>	<b>530.99</b>	<b>169.92</b>	<b>1,886.49</b>
<b>6</b>	<b>Other comprehensive income</b>				
	Items that will not be reclassified subsequently to statement of profit and loss				
	- Re-measurement (loss)/gain on defined benefit plans	(1.60)	7.95	(3.02)	(6.40)
	- Income tax effect	0.40	(2.00)	0.76	1.61
	<b>Other comprehensive income, net of tax</b>	<b>(1.20)</b>	<b>5.95</b>	<b>(2.26)</b>	<b>(4.79)</b>
<b>7</b>	<b>Total comprehensive income for the period/year (5+6)</b>	<b>760.42</b>	<b>536.94</b>	<b>167.66</b>	<b>1,881.70</b>
<b>8</b>	<b>Paid up equity share capital (face value of Rs.10 each)</b>				775.93
<b>9</b>	<b>Other Equity</b>				8,297.30
<b>10</b>	<b>Earnings / (Loss) per share (of Rs.10 each) : (not annualised for the quarter ended)</b>				
	(a) Basic (Rs.)	9.81	7.09	2.28	25.20
	(b) Diluted (Rs.)	9.81	6.97	2.26	24.77





**Notes:**

- 1 In terms of Regulation 33 of the SFBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2021 ("Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 August 2021 and have been subject to a limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Standalone financial results for the corresponding quarter ended 30 June 2020 and for the preceding quarter ended 31 March 2021, have not been subject to an audit or review by our statutory auditors. However, the management has exercised necessary due diligence to ensure that the Unaudited Standalone financial results for these periods provide a true and fair view of the Company's affairs.
- 3 The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 4 The Company has completed Initial Public Offer ("IPO") of 25,995,042 Equity Shares of the face value of Rs. 10/- each at an issue price of Rs. 825/- per Equity Share, comprising offer for sale of 23,560,538 shares by Selling Shareholders and fresh issue of 2,434,504 shares. The Equity Shares of the Company were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on 28 June 2021. Accordingly, the Unaudited Standalone Financial Results for the quarter ended 30 June 2021 are drawn up for the first time in accordance with the Listing requirements.
- 5 The utilisation of the net IPO proceeds is summarised below:


Particulars	Objects of the issue as per prospectus *	Utilisation upto 30 June 2021	Unutilised amount as on 30 June 2021
Repayment/pre-payment, in full or part, of certain borrowings availed by our Company and by our Subsidiaries	1,500.00	-	1,500.00
General Corporate Purpose	416.60	-	416.60
<b>Total</b>	<b>1,916.60</b>	<b>-</b>	<b>1,916.60</b>

\* net of Offer expenses to the extent applicable to the Fresh Issue.

IPO Proceeds, unutilised as at 30 June 2021, were temporarily invested in monitoring agency account.

- 6 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 7 The Company operates in one single reportable business segment - "Medical and Healthcare services".
- 8 The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Company is closely monitoring the impact of the pandemic on all aspects of its business, including how it will impact its employees, vendors and business partners. The Company based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact. Based on the current estimates, the Company expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic condition.
- 9 The above Unaudited Standalone Financial Results of the Company are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.

Hyderabad  
10 August 2021

For and on behalf of the Board  
**Krishna Institute of Medical Sciences Limited**  
  
**Dr. B Bhaskara Rao**  
Managing Director  
DIN: 00008985



**Press Release**

 10<sup>th</sup> August, 2021, Hyderabad, India

**Krishna Institute of Medical Sciences Limited : Results for Q1 FY 2021-22**

The Board of Directors of Krishna Institute of Medical Sciences Limited (KIMS Hospitals) today approved the financial results for the first quarter ended June 30<sup>th</sup>, 2021.

Brief snapshot of Consolidated Financial and Operational highlights are as follows :

**Financial highlights**

Particulars	YoY			(Rs in Mn) QoQ	
	Q1 FY 2021-22	Q1 FY 2020-21	% Change	Q4 FY 20-21	% Change
Total Income incl Other income	4,775	2,055	132%	3,627	32%
EBITDA	1,479	401	269%	1,051	41%
EBITDA %	31.0%	19.5%		29.0%	
PBT	1,245	140	789%	810	54%
PAT	920	89	931%	586	57%
PAT %	19.3%	4.3%		16.2%	
EPS - Diluted (Rs.)	11.48	1.48	676%	7.59	51%

**Operational highlights**

Particulars	YoY			QoQ	
	Q1 FY 2021-22	Q1 FY 2020-21	% Change	Q4 FY 20-21	% Change
IP Volume	31,709	23,203	37%	32,732	-3%
OP Volume	1,82,499	1,30,553	40%	2,61,867	-30%
ARPOB (Rs)	27,289	17,145	59%	21,591	26%
ARPP (Rs)	1,49,132	86,540	72%	1,09,234	37%

Q1 FY22 revenue and EBITDA growth is partly on account of the low base during the last financial year due to lock down, which makes Q1 FY21 not a comparable quarter. Growth during Q1 FY22 was on account of following:

- Contribution from ECMO and Heart & Lung Transplant program has doubled compared to previous quarter.
- Higher occupancy of COVID patients.
- In addition, Vaccination revenue, RTPCR tests, COVID home care and COVID hotel packages also contributed significantly.

**Clinical achievements during the Quarter**

During this unprecedented COVID crisis, KIMS rose to the occasion and did exemplary work by saving many lives in tough situations. Few of them are highlighted :

- Asia's largest number of COVID lung transplants : 20 till 30th June

**Krishna Institute of Medical Sciences Limited**

Minister Road, Secunderabad - 500 003, Telangana, India  
 Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com  
 CIN: U55101TG1973PLC040558

- In anticipation of increasing needs, we acquired additional ECMO machines and it had enormously helped in treating COVID patients effectively. We now have 18 ECMO machines and this is possibly the largest number in a single centre in the country and we treated nearly 50 plus COVID patients on ECMO machines out of which 10 were doctors brought from various parts of the country, who were serving COVID patients.
- Youngest COVID survivor, just a week old, was successfully treated and discharged from our mother and child unit which is a matter of pride and satisfaction.
- India's First known ECMO case of a COVID positive child was successfully treated and discharged.

Alongside COVID cases, we have done significant Non-COVID work:

- A pre-term baby weighing only 1100 grams was successfully discharged after undergoing a heart procedure.
- A Rare Kidney transplant between two non-compatible blood groups was successfully done.
- A 3-month-old baby underwent a rare spine deformity surgery.
- An Infant born with a rare and complex Rh issue was successfully treated.
- Advanced plasma transplantation was performed on a 6-year-old suffering with rare genetic condition

Successful treatment of such critical cases is a matter of great professional satisfaction and speaks volumes about professional expertise and medical infrastructure available with us.

#### **Commenting on the performance, Dr. B. Bhaskara Rao, Managing Director said**

"The COVID second wave was its peak during April and May 21. With learnings from the first wave, we implemented several measures like doubling up Oxygen storing tanks to hiring additional manpower especially in Nursing. I am happy to note that our doctors, nurses and admin people displayed the exemplary commitment and went above and beyond the call of duty to serve COVID patients. Despite many challenges like shortage of medicines and medical oxygen, the team laboured on day in and day out.

While critical surgeries like transplants, trauma, etc continued, elective surgeries were impacted. However, we have now seen the OP footfalls coming back to near normal and IP numbers are picking up too significantly. With strong push on Vaccinations by the Government, we are confident that this should come back to near normal soon notwithstanding the sporadic spikes being reported in few parts of the country"

#### **About KIMS Hospitals**

Founded by Dr. B. Bhaskara Rao and headquartered in Hyderabad, KIMS Hospitals is one of the largest corporate healthcare group in AP and Telangana, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. Presently, we have 9 multi-specialty hospitals under the "KIMS Hospitals" brand, with an aggregate bed capacity of 3064 beds.

For further details, please contact us at [vikas@kimshospitals.com](mailto:vikas@kimshospitals.com)

**Krishna Institute of Medical Sciences Limited**

Minister Road, Secunderabad - 500 003, Telangana, India  
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | [kimshospitals.com](http://kimshospitals.com)  
CIN: U55101TG1973PLC040558